Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2025 Jun 10;29(1):234.
doi: 10.1186/s13054-025-05473-w.

Prevalence of thromboembolic events in critically-ill COVID-19 patients infected with Omicron: results from the French prospective, multicenter SEVARVIR cohort study

Pierre Bay  1   2   3 , Etienne Audureau  4   5   6 , Slim Fourati  7   4   8 , Nicolas de Prost  9   10   7   4 ; SEVARVIR investigators
Collaborators, Affiliations
Comment

Prevalence of thromboembolic events in critically-ill COVID-19 patients infected with Omicron: results from the French prospective, multicenter SEVARVIR cohort study

Pierre Bay et al. Crit Care. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethical approval and consent to participate: The study was approved by the Comité de Protection des Personnes Sud-Méditerranée I (N° EudraCT/ID-RCB: 2021-A02914-37). Informed consent was obtained from all patients or their relatives. Competing Interests: S.F. has served as a speaker for GlaxoSmithKline, AstraZeneca, MSD, Pfeizer, Cepheid and Moderna. E.A. has received fees for lectures from Alexion, Sanofi, Gilead and Pfizer. His hospital has received research grant from Pfizer, MSD and Alexion. D.D. served as an advisor for Gilead-Sciences, ViiV Health care, Janssen-Cilag et MSD. N.D.P has served as an advisor or speaker for Moderna and AstraZeneca. P.B. has no conflict of interest to disclose.

Figures

Fig. 1
Fig. 1
Prevalence of CTPA and PE in critically-ill COVID-19 patients, according to the infecting variant or sublineage. CTPA Computed tomography pulmonary angiogram; PE Pulmonary embolism; w/o Without
See this image and copyright information in PMC

Comment on

References

    1. Faske A, Reis S, Pscheidl T, Saal-Bauernschubert L, Meybohm P, Weibel S. An urgent call to publish COVID-19 trials: a systematic search revealed ZERO studies regarding the incidence of thromboembolic events in SARS-CoV-2 Omicron-infected COVID-19 patients. Crit Care. 2025;29(1):173. - PMC - PubMed
    1. Carabelli AM, Peacock TP, Thorne LG, Harvey WT, Hughes J, COVID-19 Genomics UK Consortium, et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nat Rev Microbiol. 2023 Mar;21(3):162–77. - PMC - PubMed
    1. de Prost N, Audureau E, Heming N, Gault E, Pham T, Chaghouri A, et al. Clinical phenotypes and outcomes associated with SARS-CoV-2 variant Omicron in critically ill French patients with COVID-19. Nat Commun. 2022;13(1):6025. - PMC - PubMed
    1. de Prost N, Audureau E, Guillon A, Handala L, Préau S, Guigon A, et al. Clinical phenotypes and outcomes associated with SARS-CoV-2 Omicron sublineage JN.1 in critically ill COVID-19 patients: a prospective, multicenter cohort study in France, November 2022 to January 2024. Ann Intensive Care. 2024;14(1):101. - PMC - PubMed
    1. Katsoularis I, Fonseca-Rodríguez O, Farrington P, Jerndal H, Lundevaller EH, Sund M, et al. Risks of deep vein thrombosis, pulmonary embolism, and bleeding after covid-19: nationwide self-controlled cases series and matched cohort study. BMJ. 2022;6(377): e069590. - PMC - PubMed

LinkOut - more resources